Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

204 results about "Acinetobacter baumannii" patented technology

Acinetobacter baumannii is a typically short, almost round, rod-shaped (coccobacillus) Gram-negative bacterium. It is named after the bacteriologist Paul Baumann. It can be an opportunistic pathogen in humans, affecting people with compromised immune systems, and is becoming increasingly important as a hospital-derived (nosocomial) infection. While other species of the genus Acinetobacter are often found in soil samples (leading to the common misconception that A. baumannii is a soil organism, too), it is almost exclusively isolated from hospital environments. Although occasionally it has been found in environmental soil and water samples, its natural habitat is still not known.

Affinity purified human polyclonal antibodies and methods of making and using them

InactiveUS20100150942A1Antibody ingredientsImmunoglobulinsBacteroidesAffinity purified antibody
The present invention describes a method for treating, removing or preventing a bacterial infection, which method comprises administering to a human suffering, suspected of suffering or at risk of suffering from Staphylococcus aureus (S. aureus) infection, a Streptococcus infection, Escherichia coli (E. coli) infection, Pseudomonas aeruginosa (P. aeruginosa) infection, Acinetobacter baumannii (A. baumannii) infection, Enterococcus faecium (E. faecium) infection and / or Clostridium difficile (C. difficile) infection, an effective amount of human polyclonal antibodies affinity purified from a human blood sample with an antigenic preparation comprising cellular and / or secreted antigen(s) from bacterial cells selected from S. aureus, a Streptococcus, E. coli, P. aeruginosa, A. baumannii, E. faecium, C. difficile or a combination thereof, and optionally, wherein said affinity purified human polyclonal antibodies are purified (e.g., as made more concentrated as compared to the starting or unpurified material) relative to the same human polyclonal antibodies in the unpurified or non-affinity-purified human blood sample, e.g., intravenous immunoglobulin (IVIG) sample, and / or also optionally, wherein said affinity purified human polyclonal antibodies are specific for the bacterial antigens used in the affinity purification, and / or further optionally wherein the affinity purified human polyclonal antibodies are substantially free of human antibodies that specifically bind to non-bacterial antigens in the human blood sample. Pharmaceutical compositions for treating bacterial infections, comprising an effective amount of human polyclonal antibodies affinity purified from a human blood sample with an antigenic preparation comprising cellular and / or secreted antigen(s) from S. aureus, Streptococcus, E. coli, P. aeruginosa, A. baumannii, E. faecium, C. difficile or a combination thereof, are also provided.
Owner:SCANTIBODIES LAB

Bacteria capable of removing organic matter and ammonia nitrogen in micro-polluted water source water under low temperature and aerobic condition, and screening and taming method

The invention discloses bacteria capable of synchronously removing organic substances and ammonia nitrogen in water of a slightly polluted water source under low-temperature and aerobic conditions and a screening and domesticating method, which relate to bacteria and a screening and domesticating method and solve the problem that the prior bacteria are unsuitable for treating the slightly polluted water source as well as low temperature treatment. The bacteria SRA10 of the invention are acinetobacter lwoffi which belong to acinetobacter baumannii and are preserved in China General Microbiological Culture Collection Center on January 19th, 2009, with a preservation number of CGMCC No.2889. The screening method comprises the following steps: I, separating and purifying; II, preparing bacterial solution; III, screening and cultivating a bacterial solution; IV, screening and cultivating a bacterial solution with a live strain; V, repeating the step IV for 1 to 2 times, and stepwise domesticating the live strain; and VI, taking a bacterial solution of the domesticated strain, and rescreening the bacterial solution to obtain the bacteria. The bacteria obtained by screening and domesticating can process water of the slightly polluted water source under a condition of a low temperature of 2 to 10 DEG C.
Owner:HARBIN INST OF TECH

Biological preparation for treating high-concentration ammonia nitrogen wastewater and preparation method thereof

The invention discloses a biological preparation for treating high-concentration ammonia nitrogen wastewater. Preparation raw materials of the biological preparation are prepared from the following components in parts by weight: 10 to 15 parts of chlorella DH2 algal liquid, 20 to 30 parts of pseudomonas hibiscus DT1 fermented bacterial liquid, 15 to 20 parts of bacillus megaterium NCT-2 fermentedbacterial liquid, 10 to 15 parts of acinetobacter baumannii AL-6 fermented bacterial liquid, 5 to 10 parts of photosynthetic bacteria fermented bacterial liquid, 1 to 3 parts of agar and 3 to 5 partsof polyvinyl alcohol. In addition, the invention also provides a preparation method of the biological preparation for treating high-concentration ammonia nitrogen wastewater. According to the biological preparation, ammonia nitrogen in the high-concentration ammonia nitrogen wastewater is efficiently removed by utilizing a synergistic effect of heterotrophic nitrifying and aerobic denitrifying bacteria and chlorella; further, a nitrification process and a denitrification process of the biological preparation are carried out in the same device; a procedure is simple; a different procedure combination does not need to be set, and not only is the treatment efficiency of the wastewater improved, but also the running cost is saved.
Owner:XIAMEN UNIV OF TECH

Administration of negamycin or deoxynegamycin for the treatment of bacterial infections

The invention provides a method for treating bacterial infections. In one aspect, the invention comprises orally administering a pharmaceutical composition to an animal, wherein the composition comprises a pharmaceutically acceptable excipient and an antibacterial effective amount of negamycin, or a pharmaceutically acceptable salt, prodrug or isomer thereof. An aspect of the invention also relates to a method of treating a bacterial infection, wherein the method comprises intravenously administering a pharmaceutical composition to an animal, and wherein the composition comprises a pharmaceutically acceptable excipient and an antibacterial effective amount of deoxynegamycin, or a pharmaceutically acceptable salt, prodrug or isomer thereof. An aspect of the invention also relates to a method of treating a bacterial infection, wherein the method comprises administering to an animal an antibacterial effective amount of negamycin or deoxynegamycin, or a pharmaceutically acceptable salt, prodrug or isomer thereof, and wherein the infecting bacteria are selected from a group of bacteria consisting of the following: Acinetobacter baumanii, Citrobacter freundii, Enterobacter aerogenes, haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus MRSA, Staphylococcus aureus GISA, Staphylococcus epidermis, Streptococcus pneumoniae PenR, Streptococcus pneumoniae PenS and Streptococcus pyogenes.
Owner:VERSICOR

Primer group and kit for rapidly identifying respiratory tract microorganisms based on nanopore sequencing and application of primer group

The invention discloses a primer group for detecting respiratory tract microorganisms based on a nanopore sequencing method. The nucleotide sequences of the primer group are as shown in SEQ ID NO:1-20. The microorganisms are streptococcus pneumoniae, staphylococcus aureus (resisting to methicillin), klebsiella pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii, stenotrophomonas maltophilia, candida albicans, haemophilus influenzae, legionella pneumophila, enterococcus faecium, chlamydia psittaci, cryptococcus gattii, aspergillus fumigatus and pneumocystis jiroveci. According to the invention, sequencing optimization is carried out on different types of samples of the respiratory tract microorganisms, so that the detection method, the kit and the like are suitable for various typesof respiratory tract samples; and a targeted amplification method is adopted, so that the detection requirements of sputum, alveolar lavage and other sample types can be met. In addition, parallel sequencing can be performed, so that the flux of the detected samples is increased, the sequencing time is shortened, and the contradiction between the flux of detected pathogenic species and the cost and time is further relieved.
Owner:GUANGZHOU DARUI BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products